Angela Maas on Muck Rack

Angela Maas

Verified
Washington, D.C.
As seen in: Atlantic Information Services, Daily Mail, Irish Daily Mail, The Pink Sheet, Building Operating Management, EMJ- European Medical Journal, FacilitiesNet, Inkl, MMIT (Managed Markets Insight & Technology), RadcliffeCardiology.com, hebban.nl
AISReform is now tweeting as AIS Health. Follow @AISHealth for news and strategies on the giant transformation taking place in the health care industry.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Angela

Contact Angela, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Part B Negotiation Proposal Would Lower Prices In MA, Private Plans Too, Stakeholders Complain

|
By Cathy Kelly , Tim Casey, Sarah Karlin-Smith, Angela Maas 
| The Pink Sheet
The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches. Medicare negotiated prices could erode oncology drug and other physician administered treatment prices in the broader US insurance market.
Open in Who Shared Issue with article?

How Could MFN Pricing Impact Commercial Market?

|
By Angela Maas 
| The Pink Sheet
How Could MFN Pricing Impact Commercial Market? Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry. Experts believe insurers would like the MFN policy's reduction of utilization costs. (Shutterstock)
Open in Who Shared Issue with article?

Even at 10% Discount, Eylea Biosimilar Pavblu Offers Lower-Cost Option

|
By Angela Maas 
| MMIT (Managed Markets Insight & Technology)
Although the FDA has approved five biosimilars of Regeneron Pharmaceuticals, Inc.’s best-selling Eylea (aflibercept), patent infringement lawsuits by the drugmaker have kept those competitors off the U.S. market — until now. Following a successful defense of its Pavblu (aflibercept-ayyh), Amgen Inc. recently launched the drug at risk. The agent is entering an increasingly crowded therapeutic class, but it’s one that’s also costly for payers, which may be seeking some savings, say industry experts.
Open in Who Shared Issue with article?
See all 202 licensed articles (205 Total)

Actions

Share this page

Get in touch with Angela

Contact Angela, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified